Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction
<p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a cu...
Saved in:
| Main Author: | Rasha Kaddoura (12506936) (author) |
|---|---|
| Other Authors: | Ashfaq Patel (16855122) (author) |
| Published: |
2023
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203
by: Dr Rasha Kaddoura (17823434)
Published: (2024) -
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis
by: Dr. Rasha Kaddoura (17823428)
Published: (2024) -
Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis
by: Alaa Rahhal (14150403)
Published: (2022) -
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction in patients without diabetes in Qatar.
by: Dina Abushanab (10696501)
Published: (2024) -
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
by: Rasha Kaddoura (12506936)
Published: (2022)